PET Scan Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
Tests a PET scan tracer in adults with leukemia, melanoma, or lung cancer.
Plain-language title generated from the registry record
Registry title: PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
Key facts
- Where
- Turku, FinlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT05212103, who can take part
Where in Finland
- Turku University Hospital, Turku PET CentreTurku, FinlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT05212103
- Record updated
- 4 December 2024
- Original description
This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.Read full original descriptionShow less
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.
Inclusion: Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures; Diagnosis of metastatic melanoma and fit for immune checkpoint inhibitors or BRAF- and MEK inhibitors; Diagnosis of metastatic non-small cell lung cancer (NSCLC) (stage IV) and fit for immune checkpoint inhibitors and/or chemotherapy; Able and willing to give written informed consent and to comply with the study protocol.
Exclusion: Unsuitable for alloHSCT (AML), checkpoint inhibitors or BRAF- and MEK inhibitors (melanoma or checkpoint inhibitors and/or chemotherapy (NSCLC) according to the standard operating procedures; Evidence of significant uncontrolled concomitant diseases such as neurological, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the Investigator, would preclude patient participation; Unable or unwilling to comply with the study protocol for any reason.